SINOPHARM [01099] Announces February 2026 Monthly Return on Securities Movements

Bulletin Express03-05

SINOPHARM [01099] disclosed its monthly return for equity securities for the period ended 28 February 2026. The updated figures show that authorized share capital reached 3.12 billion shares (RMB 1 par value). No changes in authorized or registered share capital were recorded during the month.

Regarding H shares listed on The Stock Exchange of Hong Kong, the number of issued shares remained at 1.34 billion, while the balance for domestic shares not listed stood at 1.78 billion. There were no treasury shares, cancellations, or new issuances during the reporting period. Additionally, sufficiency of the public float requirement for H shares was confirmed.

No other movements, such as share options, warrants, convertibles, or agreements to issue shares, were reported. The announcement was submitted by the company secretary on 5 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment